Avalon GloboCare Provides Update On New Commercial Strategy; Continues To Implement Major Change In Strategy Focused On Acquiring And Operating Accretive Revenue Generating Laboratories And Related Commercialized Products
Portfolio Pulse from Happy Mohamed
Avalon GloboCare Corp. (NASDAQ:ALBT) has updated its commercial strategy, focusing on acquiring and operating revenue-generating laboratories and commercialized products. The company has acquired a 40% interest in Laboratory Services MSO, LLC (LSM), which generated $14.7 million in revenue and $6.3 million in net income in 2022. Avalon also secured exclusive distribution rights for the KetoAir™ breathalyzer device in North America, South America, the U.K., and the European Union. The company is also working on joint patent filings with the Massachusetts Institute of Technology (MIT).
July 10, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avalon GloboCare Corp. is focusing on acquiring and operating revenue-generating labs and commercialized products. It has acquired a 40% interest in LSM and secured distribution rights for the KetoAir™ breathalyzer device.
Avalon's new strategy of acquiring and operating revenue-generating labs and commercialized products could potentially increase its revenue and profitability. The acquisition of a 40% interest in LSM, which has a strong financial track record, and the exclusive distribution rights for the KetoAir™ breathalyzer device, could provide new revenue streams for the company. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100